Express Scripts excludes Lilly's new low cost insulin generic

Express Scripts Holding Co. (NASDAQ:ESRX) excluded from its 2019 formulary Eli Lilly's newly launched generic insulin product, reinforcing the idea that PBMs want bigger rebates, not cheaper drugs.